GBT Overview
Upcoming Projects (GBT)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (GBT)
-
A look at Global Blood Therapeutics' Sickle Cell disease therapeutics including the continued use of Oxbryta and the potential of inclacumab
Ticker: GBT
Executed On: Jun 14, 2022 at 03:30 PM EDT
Expired Projects (GBT)
-
Checking on the Oxbryta launch amid continued COVID-19 uncertainty
Ticker: GBT
Execute By: Sep 30, 2021
Upcoming & Overdue Catalysts (GBT)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (GBT)
-
Phase 3 Voxelotor HOPE Part A
Ticker: GBT
Occurred on: Jun 27, 2018 -
Top-line data due 1H 2019 for Global Blood Therapeutics'(GBT) GBT440 - HOPE Sickle cell disease in adults
Ticker: GBT
Occurred on: Jun 27, 2018 -
Upcoming Presentations of GBT440 Data in patients with the HBSC genotype sickle cell expected at ASCAT and SCDAA conferences
Ticker: GBT
Occurred on: Oct 28, 2017 -
FDA Approves Design for Global Blood's (GBT) Phase 3 Hope Trial Evaluating GBT440 in Sickle Cell Disease
Ticker: GBT
Occurred on: Oct 24, 2016 -
Global Blood Therapeutics Receives FDA Orphan Drug Designation for GBT440 in Sickle Cell Disease
Ticker: GBT
Occurred on: Dec 31, 2015
Strategic Initiatives (GBT)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
